In this free webinar, gain an understanding of the market shift of cell and gene therapies (CGTs) beyond cancer to address autoimmune diseases. Attendees will learn how innovative immunomodulatory techniques are enabling new treatment possibilities. The featured speakers will discuss the key factors needed to successfully develop and deliver CGTs for autoimmune diseases. The speakers will also share how CGTs could transform autoimmune care by offering long-term remission instead of symptom management.
TORONTO, April 15, 2025 /PRNewswire-PRWeb/ -- The landscape of cell and gene therapies (CGTs) is undergoing a significant transformation, expanding beyond oncology into the treatment of autoimmune diseases.
This shift is driven by the success of chimeric antigen receptor (CAR)-T therapies in hematologic malignancies, the growing unmet need in autoimmune disorders and advancements in immunomodulatory techniques such as regulatory T cells (Tregs) and gene editing technologies like CRISPR. Additionally, regulatory agencies and biopharmaceutical companies are increasingly investing in this field, recognizing its potential for widespread clinical impact.
With over 80 recognized autoimmune diseases affecting millions globally, existing treatments rely on symptom management rather than curative approaches. The application of CGTs offers a promising new frontier for restoring immune tolerance and achieving long-term remission; however, the unique challenges such as disease complexity, immune system risks, scalability and cost considerations must be carefully navigated.
The successful implementation of CGTs for autoimmune diseases requires an approach that integrates expertise in immunology, genetic and cellular engineering and regulatory compliance for living therapies. Patient-physician engagement and education are also critical for adoption and accessibility.
This webinar will explore the key drivers behind the transition from oncology to autoimmune and the essential considerations needed to advance CGTs in autoimmune disease treatment. Through case studies and industry insights, this webinar will provide a comprehensive overview of the shift in clinical research priorities and the future of CGTs in autoimmune disease treatment.
Register for this webinar to explore the exciting evolution in regenerative medicine and immunotherapy.
Join experts from Allucent, Desmond Cabrera, Vice President, Global Head, Cell and Gene Therapy; Dr. Brian Abbott, MD, Executive Medical Director, Therapeutic Area Medical Lead, Oncology/Hematology; and Stephanie Stempf, Project Director, Global Project Leadership, Clinical Project Management, for the live webinar on Wednesday, May 7, 2025, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Shifting Frontiers: Navigating the Evolution of Cell and Gene Therapies from Oncology to Autoimmune Studies.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
SOURCE Xtalks
Share this article